Financial News

Financial Report: Alexion

Revenues up 19% for the quarter and 18% for the year

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion

4Q Revenues: $831 million (+19)

4Q Earnings: $93 million (+39%)

FY Revenues: $3.1 billion (+18%)

FY Earnings: $399 million (+177%)

Comments: Soliris sales were $2.8 billion for the year, up 10%. Strensiq sales were $210 million, compared to $12 million in 2015. Kanuma sales were $29 million. R&D expenses were $757 million for the year, up 7%.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters